ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

BRINEURA
Miscellaneous neurodegenerative disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

BRINEURA Rx

Generic Name and Formulations:
Cerliponase alfa 30mg/mL; soln for intraventricular infusion.

Company:
BioMarin Pharmaceuticals

Therapeutic Use:

Indications for BRINEURA:

To slow the loss of ambulation in late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Adult:

Not applicable.

Children:

<3yrs: not established. See full labeling. Give by intraventricular infusion via implanted access device; administer first dose at least 5–7 days post-implantation. Pre-treat with antihistamines ± antipyretics or corticosteroids 30–60mins prior to infusion. Infuse Brineura first, followed by Intraventricular Electrolytes each at a rate of 2.5mL/hr. ≥3yrs: 300mg once every other week.

Contraindications:

Patients with acute intraventricular access device-related complications (eg, leakage, device failure, infection) or ventriculoperitoneal shunts.

Warnings/Precautions:

Should be administered by trained healthcare providers. Inspect the scalp to ensure access device is not compromised prior to each infusion. Discontinue if access device-related complications develop. Routinely test CSF samples to detect subclinical device infections. Monitor BP and HR before starting, during, and post-infusion. History of bradycardia, conduction disorder, structural heart disease: perform ECG during infusion; without cardiac abnormalities: perform ECG every 6 months. Have appropriate medical treatment available. Discontinue immediately if anaphylaxis or severe hypersensitivity reactions occur. Pregnancy. Nursing mothers.

Interactions:

Do not mix with other drugs.

Pharmacological Class:

Hydrolytic lysosomal N-terminal tripeptidyl peptidase.

Adverse Reactions:

Pyrexia, ECG abnormalities, CSF protein increase/decrease, vomiting, seizures, hypersensitivity, hematoma, headache, irritability, pleocytosis, device-related infection, bradycardia, feeling jittery, hypotension; cardiovascular events.

Generic Availability:

NO

How Supplied:

Single-dose vials (5mL)—2 (w. Intraventricular Electrolytes 5mL vial) + Administration Kit—1 (infusion supplies)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs